Effect of inhaler drug education on fatigue, dyspnea severity, and respiratory function tests in patients with COPD

Basit Öğe Kaydı
dc.authoridParlar Kılıç, Serap/0000-0003-3721-5083
dc.authoridKILIÇ, SERAP PARLAR/0000-0003-3721-5083
dc.authorwosidAytaç, Sema/ADI-6795-2022
dc.authorwosidParlar Kılıç, Serap/HIZ-6610-2022
dc.authorwosidKILIÇ, SERAP PARLAR/AAE-7903-2021
dc.contributor.authorAytac, Sema Ozoglu
dc.contributor.authorKilic, Serap Parlar
dc.contributor.authorOvayolu, Nimet
dc.date.accessioned2024-08-04T20:46:57Z
dc.date.available2024-08-04T20:46:57Z
dc.date.issued2020
dc.departmentİnönü Üniversitesien_US
dc.description.abstractObjective: This study was conducted to examine the effect of inhaler drug education on fatigue, dyspnea severity, and respiratory function tests in patients with chronic obstructive pulmonary disease (COPD). Methods: This randomized controlled study was conducted with a total of 85 patients treated at the chest diseases clinic and outpatient clinic of a state hospital. The data were collected using questionnaires, respiratory function tests, and the COPD and Asthma Fatigue Scale (CAFS) and Visual Analogue Scale (VAS-for dyspnea severity). Results: It was determined that after 4 weeks of inhaler drug education, the CAFS mean score decreased to 35.32 +/- 14.36, the dyspnea severity mean score decreased to 4.76 +/- 2.50, and the respiratory function tests mean scores increased to forced expiratory volume in 1 s (FEV1) = 58.83 +/- 25.48, forced vital capacity (FVC) = 59.04 +/- 19.19, and FEV1/FVC = 88.39 +/- 21.59 in the intervention group (p < 0.05). No change was observed in the patients in the control group except for FEV1 and FVC mean scores (p> 0.05). Conclusion: These results demonstrate that inhaler drug education can improve fatigue, dyspnea severity, and respiratory function tests of patients with COPD. Practice implications: The training by nurses of every patient hospitalized in the clinic regarding inhaler drug therapy, and the regular checking of patients' way of using the inhaled drugs, will contribute to COPD management. (C) 2019 Published by Elsevier B.V.en_US
dc.identifier.doi10.1016/j.pec.2019.11.003
dc.identifier.endpage716en_US
dc.identifier.issn0738-3991
dc.identifier.issn1873-5134
dc.identifier.issue4en_US
dc.identifier.pmid31733985en_US
dc.identifier.scopus2-s2.0-85075436978en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage709en_US
dc.identifier.urihttps://doi.org/10.1016/j.pec.2019.11.003
dc.identifier.urihttps://hdl.handle.net/11616/99068
dc.identifier.volume103en_US
dc.identifier.wosWOS:000523305400006en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherElsevier Ireland Ltden_US
dc.relation.ispartofPatient Education and Counselingen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectCOPDen_US
dc.subjectDyspneaen_US
dc.subjectFatigueen_US
dc.subjectInhaler drug therapyen_US
dc.subjectPatienten_US
dc.subjectEducationen_US
dc.titleEffect of inhaler drug education on fatigue, dyspnea severity, and respiratory function tests in patients with COPDen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu